{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:50:34Z","timestamp":1780109434204,"version":"3.54.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001785","name":"Flinders University","doi-asserted-by":"publisher","award":["FIPRS2015"],"award-info":[{"award-number":["FIPRS2015"]}],"id":[{"id":"10.13039\/501100001785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Studies have demonstrated that heart failure (HF) patients who receive direct pharmacist input as part of multidisciplinary care have better clinical outcomes. This study evaluated\/compared the difference in prescribing practices of guideline-directed medical therapy (GDMT) for chronic HF patients between two multidisciplinary clinics\u2014with and without the direct involvement of a pharmacist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective audit of chronic HF patients, presenting to two multidisciplinary outpatient clinics between March 2005 and January 2017, was performed; a Multidisciplinary Ambulatory Consulting Service (MACS) with an integrated pharmacist model of care and a General Cardiology Heart Failure Service (GCHFS) clinic, without the active involvement of a pharmacist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MACS clinic patients were significantly older (80 vs. 73\u00a0years,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001), more likely to be female (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001), and had significantly higher systolic (123 vs. 112\u00a0mmHg,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001) and diastolic (67 vs. 60\u00a0mmHg,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05) blood pressures compared to the GCHF clinic patients. Moreover, the MACS clinic patients showed more polypharmacy and higher prevalence of multiple comorbidities. Both clinics had similar prescribing rates of GDMT and achieved maximal tolerated doses of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in HFrEF. However, HFpEF patients in the MACS clinic were significantly more likely to be prescribed ACEIs\/ARBs (70.5% vs. 56.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0314) than the GCHFS patients. Patients with both HFrEF and HFpEF (MACS clinic) were significantly less likely to be prescribed \u03b2-blockers and mineralocorticoid receptor antagonists. Use of digoxin in chronic atrial fibrillation (AF) in MACS clinic was significantly higher in HFrEF patients (82.5% vs. 58.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), but the number of people anticoagulated in presence of AF (27.1% vs. 48.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) and prescribed diuretics (84.0% vs. 94.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022) were significantly lower in HFpEF patients attending the MACS clinic. Age, heart rate, systolic blood pressure (SBP),\u00a0anemia, chronic renal failure, and other\u00a0comorbidities were the main significant predictors of utilization of GDMT in a multivariate binary logistic regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lower prescription rates of some medications in the pharmacist-involved multidisciplinary team were found. Careful consideration of demographic and clinical characteristics, contraindications for use of medications, polypharmacy, and underlying comorbidities is necessary to achieve best practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-021-01868-z","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T10:18:32Z","timestamp":1613816312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-8265","authenticated-orcid":false,"given":"Daya Ram","family":"Parajuli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Shakib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Eng-Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian E.","family":"Caughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"issue":"3","key":"1868_CR1","doi-asserted-by":"publisher","first-page":"e799","DOI":"10.1097\/MJT.0000000000000065","volume":"23","author":"A Al-Khazaali","year":"2016","unstructured":"Al-Khazaali A, Arora R, Helu HK. Effective strategies in reducing rehospitalizations in patients with heart failure. Am J Ther. 2016;23(3):e799-804.","journal-title":"Am J Ther"},{"issue":"1","key":"1868_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12875-016-0537-5","volume":"17","author":"M Fry","year":"2016","unstructured":"Fry M, McLachlan S, Purdy S, Sanders T, Kadam UT, Chew-Graham CA. The implications of living with heart failure; the impact on everyday life, family support, co-morbidities and access to healthcare: a secondary qualitative analysis. BMC Fam Pract. 2016;17(1):139.","journal-title":"BMC Fam Pract"},{"issue":"6","key":"1868_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrcardio.2013.60","volume":"10","author":"LE Rohde","year":"2013","unstructured":"Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA. Cost-effectiveness of heart failure therapies. Nat Rev Cardiol. 2013;10(6):338\u201354.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"1868_CR4","doi-asserted-by":"publisher","first-page":"e002594","DOI":"10.1161\/CIRCHEARTFAILURE.115.002594","volume":"9","author":"KE Bergethon","year":"2016","unstructured":"Bergethon KE, Ju C, DeVore AD, Hardy NC, Fonarow GC, Yancy CW, Heidenreich PA, Bhatt DL, Peterson ED, Hernandez AF. Trends in 30-day readmission rates for patients hospitalized with heart failure. Circ Heart Fail. 2016;9(6):e002594.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"1868_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.amjmed.2014.08.024","volume":"128","author":"AM Chamberlain","year":"2015","unstructured":"Chamberlain AM, St. Sauver JL, Gerber Y, Manemann SM, Boyd CM, Dunlay SM, Rocca WA, Finney Rutten LJ, Jiang R, Weston SA, et al. Multimorbidity in heart failure: a community perspective. Am J Med. 2015;128(1):38\u201345.","journal-title":"Am J Med"},{"key":"1868_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ijcard.2015.09.093","volume":"214","author":"I Hopper","year":"2016","unstructured":"Hopper I, Skiba M, Windebank E, Brack J, Tonkin A, Krum H. Polypharmacy in heart failure: Is reducing medication safe? Int J Cardiol. 2016;214:529\u201330.","journal-title":"Int J Cardiol"},{"issue":"3","key":"1868_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.483","volume":"18","author":"EE van Riet","year":"2016","unstructured":"van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time: a systematic review. Eur J Heart Fail. 2016;18(3):242\u201352.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"1868_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891\u2013975.","journal-title":"Eur J Heart Fail"},{"key":"1868_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.31128\/AJGP-03-19-4873","volume":"48","author":"P Naing","year":"2019","unstructured":"Naing P, Forrester D, Kangaharan N, Muthumala A, Mon Myint S, Playford D. Heart failure with preserved ejection fraction. Aust J Gen Pract. 2019;48:465\u201371.","journal-title":"Aust J Gen Pract"},{"issue":"5","key":"1868_CR10","first-page":"242","volume":"21","author":"B \u00d6zlek","year":"2019","unstructured":"\u00d6zlek B, \u00d6zlek E, Kahraman S, Tekinalp M, Zencirkiran Agus H, \u00c7elik O, \u00c7il C, Do\u011fan V, Ba\u015faran \u00d6, Kaya BC, et al. Gender disparities in heart failure with mid-range and preserved ejection fraction: results from APOLLON study. Anatol J Cardiol. 2019;21(5):242\u201352.","journal-title":"Anatol J Cardiol"},{"issue":"4","key":"1868_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/phar.1556","volume":"35","author":"JE Basaraba","year":"2015","unstructured":"Basaraba JE, Barry AR. Pharmacotherapy of heart failure with preserved ejection fraction. Pharmacotherapy. 2015;35(4):351\u201360.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1868_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/ehf2.12283","volume":"5","author":"J Lauritsen","year":"2018","unstructured":"Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2018;5(4):685\u201394.","journal-title":"ESC Heart Fail"},{"key":"1868_CR13","first-page":"1230","volume":"20","author":"PK Srivastava","year":"2020","unstructured":"Srivastava PK, Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range ejection fraction. Curr Heart Fail Rep. 2020;20:1230\u20139.","journal-title":"Curr Heart Fail Rep"},{"issue":"15","key":"1868_CR14","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1161\/01.CIR.0000144474.65922.AA","volume":"110","author":"SD Solomon","year":"2004","unstructured":"Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004;110(15):2180\u20133.","journal-title":"Circulation"},{"issue":"8","key":"1868_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803\u201369.","journal-title":"Eur J Heart Fail"},{"key":"1868_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1471-2261-13-52","volume":"13","author":"M Al-Gobari","year":"2013","unstructured":"Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. \u03b2-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013;13:52.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"1868_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12916-020-01564-3","volume":"18","author":"OJ Ziff","year":"2020","unstructured":"Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, Kotecha D. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med. 2020;18(1):103.","journal-title":"BMC Med"},{"issue":"2","key":"1868_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1161\/CIRCHEARTFAILURE.112.000003","volume":"6","author":"SR Bapoje","year":"2013","unstructured":"Bapoje SR, Bahia A, Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J, Allen LA, Masoudi FA. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013;6(2):166\u201373.","journal-title":"Circ Heart Fail"},{"issue":"11","key":"1868_CR19","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124(11):1598\u2013617.","journal-title":"Circ Res"},{"issue":"11","key":"1868_CR20","first-page":"763","volume":"5","author":"JJ Hsu","year":"2017","unstructured":"Hsu JJ, Ziaeian B, Fonarow GC. Heart failure with mid-range (borderline) ejection fraction. Clin Implic Future Directions. 2017;5(11):763\u201371.","journal-title":"Clin Implic Future Directions"},{"key":"1868_CR21","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3389\/fphys.2019.00874","volume":"10","author":"I Lakhani","year":"2019","unstructured":"Lakhani I, Leung KSK, Tse G, Lee APW. Novel mechanisms in heart failure with preserved, midrange, and reduced ejection fraction. Front Physiol. 2019;10:874\u2013874.","journal-title":"Front Physiol"},{"issue":"24","key":"1868_CR22","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38(24):1883\u201390.","journal-title":"Eur Heart J"},{"issue":"24","key":"1868_CR23","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/eurheartj\/ehi499","volume":"26","author":"MJ Lenzen","year":"2005","unstructured":"Lenzen MJ, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons ML, Cleland JG. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005;26(24):2706\u201313.","journal-title":"Eur Heart J"},{"issue":"10","key":"1868_CR24","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173\u201384.","journal-title":"Eur J Heart Fail"},{"key":"1868_CR25","first-page":"Cd009889","volume":"12","author":"A Driscoll","year":"2015","unstructured":"Driscoll A, Currey J, Tonkin A, Krum H. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. Cochrane Database Syst Rev. 2015;12:Cd009889.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1868_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2174\/1574886315666200310114528","volume":"15","author":"AA Shukkoor","year":"2020","unstructured":"Shukkoor AA, George NE, Radhakrishnan S, Velusamy S, Kaliappan T, Gopalan R, Anandan P, Palanimuthu R, Balasubramanian VR. Impact of clinical audit on adherence to the guidelines directed medical therapy in patients admitted with heart failure. Curr Drug Saf. 2020;15(2):117\u201323.","journal-title":"Curr Drug Saf"},{"issue":"9","key":"1868_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.cardfail.2019.07.455","volume":"25","author":"DR Parajuli","year":"2019","unstructured":"Parajuli DR, Kourbelis C, Franzon J, Newman P, McKinnon RA, Shakib S, Whitehead D, Clark RA. Effectiveness of the pharmacist-involved multidisciplinary management of heart failure to improve hospitalizations and mortality rates in 4630 patients: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2019;25(9):744\u201356.","journal-title":"J Card Fail"},{"key":"1868_CR28","doi-asserted-by":"publisher","first-page":"100407","DOI":"10.1016\/j.cpcardiol.2018.12.004","volume":"44","author":"R Al-Bawardy","year":"2019","unstructured":"Al-Bawardy R, Cheng-Lai A, Prlesi L, Assafin M, Xu S, Chen K, Tandan S, Aneke CS, Murthy S, Pi\u00f1a IL. Heart failure postdischarge clinic: a pharmacist-led approach to reduce readmissions. Curr Probl Cardiol. 2019;44:100407.","journal-title":"Curr Probl Cardiol"},{"issue":"9596","key":"1868_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453\u20137.","journal-title":"Lancet (London, England)"},{"issue":"8","key":"1868_CR30","doi-asserted-by":"publisher","first-page":"e0161382","DOI":"10.1371\/journal.pone.0161382","volume":"11","author":"S Shakib","year":"2016","unstructured":"Shakib S, Dundon BK, Maddison J, Thomas J, Stanners M, Caughey GE, Clark RA. Effect of a multidisciplinary outpatient model of care on health outcomes in older patients with multimorbidity: a retrospective case control study. PLoS ONE. 2016;11(8):e0161382.","journal-title":"PLoS ONE"},{"issue":"6","key":"1868_CR31","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/gerona\/glr233","volume":"67","author":"G Onder","year":"2012","unstructured":"Onder G, Liperoti R, Fialova D, Topinkova E, Tosato M, Danese P, Gallo PF, Carpenter I, Finne-Soveri H, Gindin J, et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci. 2012;67(6):698\u2013704.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12","key":"1868_CR32","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574\u201385.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1868_CR33","doi-asserted-by":"publisher","first-page":"113.e111","DOI":"10.5694\/mja15.00801","volume":"204","author":"PJ Newton","year":"2016","unstructured":"Newton PJ, Davidson PM, Reid CM, Krum H, Hayward C, Sibbritt DW, Banks E, MacDonald PS. Acute heart failure admissions in New South Wales and the Australian Capital Territory: the NSW HF Snapshot Study. Med J Aust. 2016;204(3):113.e111-118.","journal-title":"Med J Aust"},{"issue":"8","key":"1868_CR34","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jchf.2017.05.001","volume":"5","author":"U Sartipy","year":"2017","unstructured":"Sartipy U, Dahlstr\u00f6m U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017;5(8):565\u201374.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"1868_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.recesp.2016.08.019","volume":"70","author":"I Gomez-Otero","year":"2017","unstructured":"Gomez-Otero I, Ferrero-Gregori A, Varela Roman A, Seijas Amigo J, Pascual-Figal DA, Delgado Jimenez J, Alvarez-Garcia J, Fernandez-Aviles F, Worner Diz F, Alonso-Pulpon L, et al. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. Rev Esp Cardiol (Engl ed). 2017;70(5):338\u201346.","journal-title":"Rev Esp Cardiol (Engl ed)"},{"issue":"6","key":"1868_CR36","doi-asserted-by":"publisher","first-page":"100407","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875","volume":"10","author":"O Vedin","year":"2017","unstructured":"Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OO, Savarese G, Dahlstrom U, Lund LH. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. 2017;10(6):100407.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"1868_CR37","doi-asserted-by":"publisher","first-page":"e001012","DOI":"10.1136\/openhrt-2019-001012","volume":"6","author":"AL Beale","year":"2019","unstructured":"Beale AL, Warren JL, Roberts N, Meyer P, Townsend NP, Kaye D. Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart. 2019;6(1):e001012.","journal-title":"Open Heart"},{"issue":"2","key":"1868_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","volume":"27","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27(2):178\u201386.","journal-title":"Eur Heart J"},{"issue":"2","key":"1868_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.amjmed.2013.08.006","volume":"127","author":"T Hashim","year":"2014","unstructured":"Hashim T, Elbaz S, Patel K, Morgan CJ, Fonarow GC, Fleg JL, McGwin G, Cutter GR, Allman RM, Prabhu SD, et al. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014;127(2):132\u20139.","journal-title":"Am J Med"},{"issue":"6","key":"1868_CR40","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/jep.12760","volume":"23","author":"V Khalil","year":"2017","unstructured":"Khalil V, Danninger M, Wang W, Khalil H. An audit of adherence to heart failure guidelines in an Australian hospital: a pharmacist perspective. J Eval Clin Pract. 2017;23(6):1195\u2013202.","journal-title":"J Eval Clin Pract"},{"issue":"6","key":"1868_CR41","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00380-017-1099-8","volume":"33","author":"M Suzuki","year":"2018","unstructured":"Suzuki M, Matsue Y, Izumi S, Kimura A, Hashimoto T, Otomo K, Saito H, Suzuki M, Kato Y, Funakoshi R. Pharmacist-led intervention in the multidisciplinary team approach optimizes heart failure medication. Heart Vessels. 2018;33(6):615\u201322.","journal-title":"Heart Vessels"},{"issue":"6","key":"1868_CR42","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/01.CIR.0000138934.28340.ED","volume":"110","author":"FA Masoudi","year":"2004","unstructured":"Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110(6):724\u201331.","journal-title":"Circulation"},{"issue":"11","key":"1868_CR43","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/qjmed\/hcv049","volume":"108","author":"W Cheungpasitporn","year":"2015","unstructured":"Cheungpasitporn W, Thongprayoon C, Chiasakul T, Korpaisarn S, Erickson SB. Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis. QJM Int J Med. 2015;108(11):879\u201384.","journal-title":"QJM Int J Med"},{"issue":"5","key":"1868_CR44","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2217\/cpr.14.46","volume":"11","author":"M Mallappallil","year":"2014","unstructured":"Mallappallil M, Friedman EA, Delano BG, McFarlane SI, Salifu MO. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond). 2014;11(5):525\u201335.","journal-title":"Clin Pract (Lond)"},{"issue":"2","key":"1868_CR45","doi-asserted-by":"publisher","first-page":"e0212907","DOI":"10.1371\/journal.pone.0212907","volume":"14","author":"RD Turgeon","year":"2019","unstructured":"Turgeon RD, Kolber MR, Loewen P, Ellis U, McCormack JP. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. PLoS ONE. 2019;14(2):e0212907\u2013e0212907.","journal-title":"PLoS ONE"},{"issue":"1","key":"1868_CR46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1471-2261-12-60","volume":"12","author":"J-Y Kim","year":"2012","unstructured":"Kim J-Y, Kim H-J, Jung S-Y, Kim K-I, Song HJ, Lee J-Y, Seong J-M, Park B-J. Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database. BMC Cardiovasc Disord. 2012;12(1):60.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"1868_CR47","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","volume":"24","author":"M Komajda","year":"2003","unstructured":"Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, et al. The EuroHeart Failure Survey programme\u2014a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464\u201374.","journal-title":"Eur Heart J"},{"issue":"5","key":"1868_CR48","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10557-017-6764-8","volume":"31","author":"EB Levitan","year":"2017","unstructured":"Levitan EB, Van Dyke MK, Loop MS, O\u2019Beirne R, Safford MM. Barriers to beta-blocker use and up-titration among patients with heart failure with reduced ejection fraction. Cardiovasc Drugs Ther. 2017;31(5):559\u201364.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"1868_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5694\/j.1326-5377.2004.tb06178.x","volume":"181","author":"SM Phillips","year":"2004","unstructured":"Phillips SM, Tofler GH, Marton RL. Barriers to diagnosing and managing heart failure in primary care. Med J Aust. 2004;181(2):78\u201381.","journal-title":"Med J Aust"},{"issue":"6","key":"1868_CR50","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.ijcard.2012.06.116","volume":"167","author":"PR Kalra","year":"2013","unstructured":"Kalra PR, Morley C, Barnes S, Menown I, Kassianos G, Padmanabhan S, Gupta S, Lang CC. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013;167(6):2695\u20139.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1868_CR51","doi-asserted-by":"publisher","first-page":"e000856","DOI":"10.1136\/openhrt-2018-000856","volume":"6","author":"XJ Chen","year":"2019","unstructured":"Chen XJ, Barywani SB, Hansson PO, \u00d6stg\u00e4rd Thunstr\u00f6m E, Rosengren A, Ergatoudes C, Mandalenakis Z, Caidahl K, Fu ML. Impact of changes in heart rate with age on all-cause death and cardiovascular events in 50-year-old men from the general population. Open Heart. 2019;6(1):e000856.","journal-title":"Open Heart"},{"issue":"12","key":"1868_CR52","doi-asserted-by":"publisher","first-page":"e006540","DOI":"10.1161\/JAHA.117.006540","volume":"6","author":"LB Cooper","year":"2017","unstructured":"Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP, Fonarow GC, Yancy CW, Heidenreich PA, Hernandez AF. Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. J Am Heart Assoc. 2017;6(12):e006540.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1868_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.15420\/cfr.2015:28:2","volume":"2","author":"L Fauchier","year":"2016","unstructured":"Fauchier L, Laborie G, Clementy N, Babuty D. Beta-blockers or digoxin for atrial fibrillation and heart failure? Cardiac Fail Rev. 2016;2(1):35\u20139.","journal-title":"Cardiac Fail Rev"},{"issue":"9","key":"1868_CR54","doi-asserted-by":"publisher","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","volume":"6","author":"TK Teng","year":"2018","unstructured":"Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018;6(9):e1008\u201318.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"1868_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/qjmed\/hch023","volume":"97","author":"PA Mehta","year":"2004","unstructured":"Mehta PA, McDonagh S, Poole-Wilson PA, Grocott-Mason R, Dubrey SW. Heart failure in a district general hospital: are target doses of beta-blockers realistic? QJM Int J Med. 2004;97(3):133\u20139.","journal-title":"QJM Int J Med"},{"issue":"11","key":"1868_CR56","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.acvd.2009.08.011","volume":"102","author":"F Follath","year":"2009","unstructured":"Follath F. Challenging the dogma of high target doses in the treatment of heart failure: Is more always better? Arch Cardiovasc Dis. 2009;102(11):785\u20139.","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"1868_CR57","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.","journal-title":"BMC Geriatr"},{"issue":"5","key":"1868_CR58","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ahj.2012.08.002","volume":"164","author":"BD Atwater","year":"2012","unstructured":"Atwater BD, Dai D, Allen-Lapointe NM, Al-Khatib SM, Zimmer LO, Sanders GD, Peterson ED. Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. Am Heart J. 2012;164(5):750-755.e751.","journal-title":"Am Heart J"},{"issue":"4","key":"1868_CR59","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14656566.2017.1288717","volume":"18","author":"VB Polsinelli","year":"2017","unstructured":"Polsinelli VB, Shah SJ. Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother. 2017;18(4):399\u2013409.","journal-title":"Expert Opin Pharmacother"},{"issue":"30","key":"1868_CR60","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","volume":"39","author":"CSP Lam","year":"2018","unstructured":"Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39(30):2780\u201392.","journal-title":"Eur Heart J"},{"issue":"1","key":"1868_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5694\/j.1326-5377.2010.tb03393.x","volume":"192","author":"DT Wong","year":"2010","unstructured":"Wong DT, Clark RA, Dundon BK, Philpott A, Molaee P, Shakib S. Caveat anicula! Beware of quiet little old ladies: demographic features, pharmacotherapy, readmissions and survival in a 10-year cohort of patients with heart failure and preserved systolic function. Med J Aust. 2010;192(1):9\u201313.","journal-title":"Med J Aust"},{"issue":"5","key":"1868_CR62","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ejheart.2004.03.011","volume":"6","author":"J Muntwyler","year":"2004","unstructured":"Muntwyler J, Cohen-Solal A, Freemantle N, Eastaugh J, Cleland JG, Follath F. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail. 2004;6(5):663\u20138.","journal-title":"Eur J Heart Fail"},{"key":"1868_CR63","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12872-016-0425-x","volume":"16","author":"NM Berbenetz","year":"2016","unstructured":"Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:246.","journal-title":"BMC Cardiovasc Disord"},{"key":"1868_CR64","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijchv.2014.03.005","volume":"3","author":"E Vizzardi","year":"2014","unstructured":"Vizzardi E, Regazzoni V, Caretta G, Gavazzoni M, Sciatti E, Bonadei I, Trichaki E, Raddino R, Metra M. Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. IJC Heart & Vessels. 2014;3:6\u201314.","journal-title":"IJC Heart & Vessels"},{"issue":"4","key":"1868_CR65","doi-asserted-by":"publisher","first-page":"e93129","DOI":"10.1371\/journal.pone.0093129","volume":"9","author":"TH Ho","year":"2014","unstructured":"Ho TH, Caughey GE, Shakib S. Guideline Compliance in chronic heart failure patients with multiple comorbid diseases: evaluation of an individualised multidisciplinary model of care. PLoS ONE. 2014;9(4):e93129.","journal-title":"PLoS ONE"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01868-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-021-01868-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01868-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T10:20:51Z","timestamp":1613816451000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-01868-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-01868-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-70812\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the Royal Adelaide Hospital Human Ethics Research Committee (R20161105). Written consent from individual patients was not required for the above Research Ethics board as data which is routinely available within current clinical practice was used and analyzed using non-identifiable format. Further, this study was considered as a quality improvement activity, conducting an appropriate audit of a clinical service.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}